Aimei Health Technology Stock Surges 15.9%

Is the NASDAQ-listed biotech company still a buy after the recent price jump?

Mar. 14, 2026 at 5:53pm

Got story updates? Submit your updates here. ›

Aimei Health Technology Co., Ltd (NASDAQ:AFJKU) saw its stock price rise 15.9% during trading on Thursday, reaching a high of $27.61 per share. The company, which was incorporated in 2023 and is based in New York, is a blank-check firm that intends to acquire businesses in the biopharmaceutical, medical technology/device, and diagnostic sectors.

Why it matters

The significant one-day price increase in Aimei Health Technology's stock raises questions about whether the company is still an attractive investment opportunity or if the recent rally has made the stock overvalued. As a newly formed blank-check company, Aimei Health's future success will depend on its ability to identify and execute a successful merger or acquisition in the healthcare industry.

The details

Aimei Health Technology's stock closed at $23.83 on the previous trading day, before surging 15.9% to $27.61 on Thursday. Trading volume was down 68% from the average daily volume. The company's stock has a 50-day moving average price of $57.45 and a 200-day moving average of $33.36. A hedge fund, Clear Street Group Inc., recently bought a new stake in Aimei Health Technology worth approximately $26,000.

  • Aimei Health Technology's stock rose 15.9% during trading on Thursday, March 14, 2026.

The players

Aimei Health Technology Co., Ltd

A blank-check company incorporated in 2023 and based in New York that intends to acquire businesses in the biopharmaceutical, medical technology/device, and diagnostic sectors.

Clear Street Group Inc.

A hedge fund that recently bought a new stake in Aimei Health Technology worth approximately $26,000.

Got photos? Submit your photos here. ›

The takeaway

Aimei Health Technology's significant one-day stock price increase raises questions about whether the company's valuation is justified, given its status as a newly formed blank-check firm without any significant operations. Investors will be closely watching to see if Aimei Health can successfully identify and execute a value-enhancing merger or acquisition in the healthcare industry.